Atopic Dermatitis Drugs Market
Analysts’ Viewpoint on Atopic Dermatitis Drugs Market Scenario
The global atopic dermatitis drugs market is expected to grow at a rapid pace during the forecast period due to the rise in prevalence and incidence of the disease across the globe. Surge in atopic dermatitis cases has increased the need for effective treatment drugs such as cyclosporine and atopic eczema antihistamine. Governments in various developed and developing countries are participating in programs to spread awareness about atopic dermatitis medications. Similarly, development of new drugs for treating atopic dermatitis and increase in clinical trials are boosting the demand for new improved treatments for atopic dermatitis. Thus, the global atopic dermatitis market forecast appears promising due to the increase in investment by companies in the development of new treatment drugs. For instance, Sanofi and Pfizer have introduced various drugs for the treatment of atopic dermatitis. These drugs have received the U.S. FDA approval.
Atopic dermatitis, also known as eczema, is a condition that affects the skin and causes itchiness, dryness, and inflammation. The condition can be chronic and tends to flare and spread sometimes. Atopic dermatitis drugs, including atopic eczema steroids, are used to treat eczema and reduce itchiness and other conditions caused by atopic dermatitis. The global atopic dermatitis drugs market size is projected to grow at a rapid pace during the forecast period owing to the rise in investment in research & development activities and novel pipeline drugs.
Request a sample to get extensive insights into the Atopic Dermatitis Drugs Market
Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyle, age, gender, heredity, and personal habits. According to the World Health Organization (WHO), more than 900 million people were affected with skin diseases in 2017, and the five common conditions, including atopic dermatitis, accounted for around 80% of the skin disorders. High prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis affects 15% to 20% children and 1% to 3% adults across the world per year. New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to propel the global atopic dermatitis market size during the forecast period.
Usage of biologic drugs in dermatology has changed the treatment procedure of dermatological disorders, especially atopic dermatitis. Leading biopharmaceutical companies are investing significantly in biologic product development, merger & acquisitions, and strategic collaborations. Atopic dermatitis has shown positive response to biologics, which has improved the overall quality of life. Hence, overall demand for biologic drugs for atopic dermatitis has increased. This trend is likely to continue in the next few years. Just one biologic product has been approved for the treatment of atopic dermatitis to date. Many more are in phase II clinical trials and are likely to receive approvals in the near future.
Request a custom report on Atopic Dermatitis Drugs Market
In terms of drug type, the biologics segment dominated the global atopic dermatitis drugs market, with around 76% share in 2021. The trend is projected to continue during the forecast period. The segment is anticipated to be driven by the rise in prevalence of atopic dermatitis, as biologics inhibit the inflammatory response that is responsible for the development of the disease. According to the Dermatology Therapeutics Area Working Group, global prevalence rate of atopic dermatitis stands at 8% to 15% in children.
In terms of distribution channel, the global atopic dermatitis drugs market has been segmented into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacies segment held major share of around 65% in 2021. Growth of the segment can be ascribed to the increase in purchasing power of patients and surge in the number of retail pharmacies.
North America accounted for the largest share of around 46% of the global atopic dermatitis drugs market in 2021. This can be ascribed to large patient pool in the region that requires efficient and new therapies.
Europe held around 30% share of the global market in 2021. The market in the region is expected to grow at a faster pace from 2022 to 2031 due to the increase in focus on the development of health care infrastructure by governments and rise in demand for affordable, effective therapeutics among the significant patient population.
Asia Pacific accounted for larger market share than Latin America and Middle East & Africa in 2021. However, the market in Latin America is expected to grow at a faster pace than that in Middle East & Africa.
The atopic dermatitis drugs market report concludes with the company profiles section, which includes key information about major players in the global atopic dermatitis drugs market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global atopic dermatitis drugs market. Prominent players in the atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.
Each of these players has been profiled in the atopic dermatitis drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 6.0 Bn |
|
Market Forecast Value in 2031 |
More than US$ 29.4 Bn |
|
Growth Rate (CAGR) for 2022-2031 |
14.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global atopic dermatitis drugs market was valued at US$ 6.0 Bn in 2021
The global atopic dermatitis drugs market is projected to reach more than US$ 29.4 Bn by 2031
The global atopic dermatitis drugs market is anticipated to grow at a CAGR of 14.7% from 2022 to 2031
The biologics segment held around 76% share of the global atopic dermatitis drugs market in 2021
North America is expected to account for major share of the global atopic dermatitis drugs market during the forecast period.
Prominent players in the global atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Atopic Dermatitis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Key Industry Events
5.4. COVID-19 Impact Analysis
6. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Corticosteroids
6.3.2. PDE4 Inhibitors
6.3.3. Biologics
6.3.4. Skin Barrier Emollients
6.3.5. CNI Immunosuppressants
6.3.6. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Atopic Dermatitis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017–2031
9.2.1. Corticosteroids
9.2.2. PDE4 Inhibitors
9.2.3. Biologics
9.2.4. Skin Barrier Emollients
9.2.5. CNI Immunosuppressants
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Corticosteroids
10.2.2. PDE4 Inhibitors
10.2.3. Biologics
10.2.4. Skin Barrier Emollients
10.2.5. CNI Immunosuppressants
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Corticosteroids
11.2.2. PDE4 Inhibitors
11.2.3. Biologics
11.2.4. Skin Barrier Emollients
11.2.5. CNI Immunosuppressants
11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Corticosteroids
12.2.2. PDE4 Inhibitors
12.2.3. Biologics
12.2.4. Skin Barrier Emollients
12.2.5. CNI Immunosuppressants
12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Corticosteroids
13.2.2. PDE4 Inhibitors
13.2.3. Biologics
13.2.4. Skin Barrier Emollients
13.2.5. CNI Immunosuppressants
13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Mylan N.V.
14.3.1.1. Company Description
14.3.1.2. Business Overview
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Pfizer, Inc.
14.3.2.1. Company Description
14.3.2.2. Business Overview
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. LEO Pharma A/S
14.3.3.1. Company Description
14.3.3.2. Business Overview
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. Sanofi
14.3.4.1. Company Description
14.3.4.2. Business Overview
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Novartis AG
14.3.5.1. Company Description
14.3.5.2. Business Overview
14.3.5.3. Financial Overview
14.3.5.4. Strategic Overview
14.3.5.5. SWOT Analysis
14.3.6. Bausch Health
14.3.6.1. Company Description
14.3.6.2. Business Overview
14.3.6.3. Financial Overview
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Teva Pharmaceutical Industries Ltd.
14.3.7.1. Company Description
14.3.7.2. Business Overview
14.3.7.3. Financial Overview
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
List of Tables
Table 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031
Table 03: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 06: North America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 09: Europe Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 12: Asia Pacific Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 15: Latin America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 18: Middle East and Africa Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 03: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 04: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2031
Figure 05: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by PDE4 Inhibitors, 2017–2031
Figure 06: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Biologics, 2017–2031
Figure 07: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Skin Barrier Emollients, 2017–2031
Figure 08: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, CNI Immunosuppressants, 2017–2031
Figure 09: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Others, 2017–2031
Figure 10: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 11: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 12: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2017–2031
Figure 13: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2017–2031
Figure 14: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Online Pharmacies, 2017–2031
Figure 15: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Region, 2021 and 2031
Figure 16: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Region, 2022–2031
Figure 17: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 18: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Country, 2021 and 2031
Figure 19: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country, 2022–2031
Figure 20: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 21: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 22: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 23: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 24: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 26: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 27: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 28: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 29: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 30: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 31: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 33: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 34: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 35: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 36: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 37: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 38: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 39: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 40: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 41: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 42: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 43: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 44: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 45: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 47: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 48: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 49: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 50: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 51: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes